Literature DB >> 18200628

Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability.

Alfonso Fasano1, Cesare Colosimo, Hiroaki Miyajima, Pietro Attilio Tonali, Thomas J Re, Anna Rita Bentivoglio.   

Abstract

Hereditary aceruloplasminemia (HA) is a rare inherited disease characterized by anemia, iron overload, diabetes, and neurodegeneration. HA is caused by the homozygous mutation of the ceruloplasmin (CP) gene. We report two siblings with markedly different phenotypes carrying a novel mutation: a homozygous deletion of two nucleotides (1257-1258 TT del) causing the premature stop of the Cp protein translation (Y401X). An early diagnosis of iron overload was made in the female sibling who was subsequently treated with deferoxamine. At the age of 54, her neurologic symptoms were limited to mild akinetic signs and a history of seizures; moreover, her fasting blood glucose level never exceeded 120 mg/dL. The male sibling, who had not received any specific treatment for HA, developed severe diabetes at the age of 32 and at 48 manifested a progressively disabling neurologic disease. Possible physiopathological bases of these intrafamilial phenotypic variations are discussed. 2008 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18200628     DOI: 10.1002/mds.21938

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  6 in total

1.  Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.

Authors:  Niels Bergsland; Eleonora Tavazzi; Ferdinand Schweser; Dejan Jakimovski; Jesper Hagemeier; Michael G Dwyer; Robert Zivadinov
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

Review 2.  The role of iron in brain ageing and neurodegenerative disorders.

Authors:  Roberta J Ward; Fabio A Zucca; Jeff H Duyn; Robert R Crichton; Luigi Zecca
Journal:  Lancet Neurol       Date:  2014-10       Impact factor: 44.182

Review 3.  Endocrine manifestations related to inherited metabolic diseases in adults.

Authors:  Marie-Christine Vantyghem; Dries Dobbelaere; Karine Mention; Jean-Louis Wemeau; Jean-Marie Saudubray; Claire Douillard
Journal:  Orphanet J Rare Dis       Date:  2012-01-28       Impact factor: 4.123

Review 4.  Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders.

Authors:  Vassilena Iankova; Ivan Karin; Thomas Klopstock; Susanne A Schneider
Journal:  Front Neurol       Date:  2021-04-15       Impact factor: 4.003

5.  Aceruloplasminemia: a rare disease - diagnosis and treatment of two cases.

Authors:  Maria do Rosário Ferraz Roberti; Handel Meireles Borges Filho; Cláudio Humberto Gonçalves; Flávio Leão Lima
Journal:  Rev Bras Hematol Hemoter       Date:  2011

6.  Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports.

Authors:  Lena H P Vroegindeweij; Agnita J W Boon; J H Paul Wilson; Janneke G Langendonk
Journal:  Orphanet J Rare Dis       Date:  2020-04-25       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.